LCAOS

A Nanoscale Artificial Nose to easily detect Volatile Biomarkers at Early stages of Lung Cancer and Related Genetic Mutations

 Coordinatore TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY 

 Organization address address: TECHNION CITY - SENATE BUILDING
city: HAIFA
postcode: 32000

contact info
Titolo: Dr.
Nome: Birsan
Cognome: Silvia
Email: send email
Telefono: +972 4 8293560
Fax: +972 4 8295672

 Nazionalità Coordinatore Israel [IL]
 Totale costo 5˙405˙173 €
 EC contributo 4˙140˙174 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-HEALTH-2010-two-stage
 Funding Scheme CP-FP
 Anno di inizio 2011
 Periodo (anno-mese-giorno) 2011-04-01   -   2015-03-31

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY

 Organization address address: TECHNION CITY - SENATE BUILDING
city: HAIFA
postcode: 32000

contact info
Titolo: Dr.
Nome: Birsan
Cognome: Silvia
Email: send email
Telefono: +972 4 8293560
Fax: +972 4 8295672

IL (HAIFA) coordinator 1˙211˙702.39
2    THE UNIVERSITY OF LIVERPOOL

 Organization address address: Brownlow Hill, Foundation Building 765
city: LIVERPOOL
postcode: L69 7ZX

contact info
Titolo: Ms.
Nome: Veronica
Cognome: Shaw
Email: send email
Telefono: +44 151 794 8722
Fax: +44 151 794 8728

UK (LIVERPOOL) participant 654˙457.80
3    MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V.

 Organization address address: Hofgartenstrasse 8
city: MUENCHEN
postcode: 80539

contact info
Titolo: Dr.
Nome: Sabine
Cognome: Koenig
Email: send email
Telefono: +49 9131 6877500
Fax: +49 9131 6877109

DE (MUENCHEN) participant 577˙099.95
4    TEL AVIV UNIVERSITY

 Organization address address: RAMAT AVIV
city: TEL AVIV
postcode: 69978

contact info
Titolo: Ms.
Nome: Lea
Cognome: Pais
Email: send email
Telefono: 97236408774
Fax: 97236409697

IL (TEL AVIV) participant 473˙367.18
5    UNIVERSIDAD COMPLUTENSE DE MADRID

 Organization address address: AVENIDA DE SENECA 2
city: MADRID
postcode: 28040

contact info
Titolo: Ms.
Nome: Maribel
Cognome: Rodríguez Villa
Email: send email
Telefono: 34913946376
Fax: 34913946382

ES (MADRID) participant 412˙607.20
6    IONICON ANALYTIK GMBH

 Organization address address: EDUARD BODEM GASSE 3
city: INNSBRUCK
postcode: 6020

contact info
Titolo: Dr.
Nome: Jens
Cognome: Herbig
Email: send email
Telefono: +43 512 214 800 801
Fax: +43 512 214 800 899

AT (INNSBRUCK) participant 328˙320.00
7    JLM INNOVATION GMBH

 Organization address address: BEETHOVENWEG 41
city: TUEBINGEN
postcode: 72076

contact info
Titolo: Dr.
Nome: Jan
Cognome: Mitrovics
Email: send email
Telefono: +49 7071 940641
Fax: +49 7071 940642

DE (TUEBINGEN) participant 301˙435.20
8    MICRONIT MICROFLUIDICS BV

 Organization address address: COLOSSEUM 15
city: ENSCHEDE
postcode: 7521 PV

contact info
Titolo: Dr.
Nome: Marko
Cognome: Blom
Email: send email
Telefono: 31538506850
Fax: 31538506851

NL (ENSCHEDE) participant 181˙185.01
9    Ionimed Analytik GmbH

 Organization address address: Eduard-Bodem-Gasse 3
city: Innsbruck
postcode: 6020

contact info
Titolo: Dr.
Nome: Jens
Cognome: Herbig
Email: send email
Telefono: +43 512 214 800 801
Fax: +43 512 214 800 899

AT (Innsbruck) participant 0.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

risk    artificial    nose    breath    sense    inexpensive    exhaled    diagnostic    nanose    lung    detect    volatile    lc    sensitive    scientists    lcaos    biomarkers    cancer   

 Obiettivo del progetto (Objective)

'The LCAOS project will develop and test a new diagnostic tool, able to detect: (i) the presence of lung cancer (LC), and (ii) an increased risk of a patient developing LC in the future. Diagnostic tests currently available are unsuitable for widespread screening because they are costly, occasionally miss tumours, are not time-efficient, nor free of complications. LCAOS will overcome these problems by using an approach based on volatile biomarkers emitted from cell membranes. A multidisciplinary effort, incorporating nanotechnology, biomedical engineering, medical oncology, and computation strategies, will develop a highly-sensitive, inexpensive, and fast-response, non-invasive, artificial nose (known as, NaNose), building on the coordinator’s earlier success in this area. The NaNose will be able to detect pre-neoplastic volatile biomarkers that indicate an increased genetic risk of LC, and the presence of LC. It has already been established that these biomarkers can be detected either directly from the headspace of the cancer cells or via exhaled breath. LCAOS will: (i) develop arrays of chemically-sensitive field effect transistors (FETs) of non-oxidized, molecule-terminated silicon nanowires (Si NWs); (ii) test the ability of these devices to sense volatile LC biomarkers from in-vitro tissue, and exhaled human breath; (iii) study the signal transduction mechanism of the volatile biomarkers, using pattern recognition; (iv) improve systems to enable the NaNose to distinguish the targeted biomarkers from environmental clutter, using methylation, expression profiling, and genome-wide sequencing; and (v) perform clinical-related studies to assess LC conditions in actual patients & tissues, and in the presence of real-world confounding signals. Validation will be carried out by clinician partners and professional mathematicians and computer scientists. Resources will also be allocated to ensure the commercial potential of the sensor device layout.'

Introduzione (Teaser)

Lung cancer (LC) is a devastating disease whose outcomes are significantly improved with early detection. Scientists are developing an inexpensive artificial nose to analyse exhaled breath and sense increased risk.

Altri progetti dello stesso programma (FP7-HEALTH)

NEUROBID (2010)

Neuroscience on Barriers in Development

Read More  

GENINCA (2008)

Genomic instability and genomic alterations in pre-cancerous lesions and/or cancer

Read More  

CHAARM (2010)

Combined Highly Active Anti-retroviral Microbicides

Read More